ReviewJournal of clinical oncology : official journal of the American Society of Clinical Oncology2018
Gastrointestinal Stromal Tumors.
Review in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 3 registered trials, which are not on this map. Cited by 177 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Avapritinib in the Treatment of Unresectable or Recurrent Metastatic Gastrointestinal Stromal Tumors Non-exon18 Mutations of PDGFRA:A Real-world Study
A Multicenter Study of Avapritinib Efficacy and Safety of Metastatic or Unresectable Gastrointestinal Stromal Tumors
The Correlation Between Ripretinib Exposure and the Efficacy and Safety in Patients with Advanced Gastrointestinal Stromal Tumors: an Observational Study
Who cites it
177 citing papers in PubMed, 3 syntheses or guidelines pooled it, 300 citations in OpenAlex.
- Preoperative PET or PET/CT for malignant diagnosis of Gastrointestinal stromal tumors: a systematic review and meta-analysis.BMC cancer · 2026Pooled it
- Contributions of NFKB1 -94insertion/deletion ATTG polymorphism to the susceptibility of gastrointestinal cancers: A meta-analysis.Journal of cellular and molecular medicine · 2021Pooled it
- Gastric Calcifying Fibrous Tumor: An Easy Misdiagnosis as Gastrointestinal Stromal Tumor-A Systemic Review.Medicina (Kaunas, Lithuania) · 2020Pooled it
- KIT and PDGFRA Mutations and Survival of Gastrointestinal Stromal Tumor Patients Treated with Adjuvant Imatinib in a Randomized Trial.Clinical cancer research : an official journal of the American Association for Cancer Research · 2023Trial
- Development and validation of a novel diagnostic model for initially clinical diagnosed gastrointestinal stromal tumors using an extreme gradient-boosting machine.BMC gastroenterology · 2021Trial
- Trial
- Linsitinib (OSI-906) for the Treatment of Adult and Pediatric Wild-Type Gastrointestinal Stromal Tumors, a SARC Phase II Study.Clinical cancer research : an official journal of the American Association for Cancer Research · 2020Trial
- A Phase II Trial of Vandetanib in Children and Adults with Succinate Dehydrogenase-Deficient Gastrointestinal Stromal Tumor.Clinical cancer research : an official journal of the American Association for Cancer Research · 2019Trial
- Intestinal tumors in neurofibromatosis 1 with special reference to fatal gastrointestinal stromal tumors (GIST).Molecular genetics & genomic medicine · 2019Trial
- Precision oncology meets Generative AI: assessing large language models in multidisciplinary GIST tumor boards.BMC cancer · 2026Article
- Reverse Endoscopic Full-Thickness Resection for Gastric Submucosal Tumors With a Predominant Extraluminal Growth Pattern.Clinical and translational gastroenterology · 2026Article
- Cecal Gastrointestinal Stromal Tumor Mimicking an Appendiceal Inflammatory Mass: Diagnostic Challenges and Surgical Management: A Case Report.Journal of clinical medicine · 2026Article
- Targeting tumor dormancy: the next frontier in gastrointestinal stromal tumor therapy.Neoplasia (New York, N.Y.) · 2026Review
- Multi-center and multi-reader comparison of abdominopelvic non-contrast and contrast-enhanced CT in the postoperative surveillance of gastrointestinal stromal tumors.Quantitative imaging in medicine and surgery · 2026Article
- Endoscopic Full-Thickness Resection of Rectal Gastrointestinal Stromal Tumor With Endoscopic Rectal Reconstruction.ACG case reports journal · 2026Article
- A scoring model for differentiating gastric calcifying fibrous tumors from gastrointestinal stromal tumors less than 2 cm based on CT features.BMC medical imaging · 2026Article
- Tumor mutation burden predicts aggressiveness and prognosis of gastrointestinal stromal tumor.Translational cancer research · 2026Article
- Long Non-Coding RNA CTD-2245E15.3 Drives Proliferation and Migration in Gastrointestinal Stromal Tumors.Biomedicines · 2026Article
- Case Report: A liver metastasis 24 years after resection of a very low-risk jejunal gastrointestinal stromal tumor.Frontiers in oncology · 2026Article
- Gastrointestinal Stromal Tumor (GIST) Arising in the Setting of a Large Hiatal Hernia: A Case Report.International medical case reports journal · 2026Article
117 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
GI stromal tumors (GISTs) are neoplasms with a varying malignancy potential ranging from virtually indolent tumors to rapidly progressing cancers. GISTs occur throughout the intestinal tract, and most harbor an activating mutation in either KIT or platelet-derived growth factor A ( PDGFRA). Diagnosis is made using immunohistochemistry, but molecular testing with mutation analysis is paramount for selection of appropriate therapy. Most small GISTs are cured with surgery. Tyrosine kinase inhibitor (TKI) therapy has led to substantial improvements in survival, both for patients with localized GIST and those with advanced disease. Adjuvant therapy with imatinib benefits patients with a high risk of recurrence, with studies suggesting most benefit with at least 3 years of therapy. Neoadjuvant imatinib therapy should be considered for patients requiring extensive surgery, aiming at shrinking the tumor to allow organ preservation and less extensive surgery. The following three TKIs have been approved for the management of advanced disease: imatinib, sunitinib, and regorafenib; imatinib is usually the best tolerated of the three and the standard first-line treatment. TKIs benefit the majority of patients with advanced GIST but have no or limited efficacy in patients with the PDGFRA D842V mutation or patients with GIST lacking KIT and PDGFRA mutations. Surgery, the mainstay of primary tumor management, also plays a role in the advanced disease setting for selected patients, as do some other approaches such as palliative radiation therapy. Research continues to identify novel therapies, in particular effective agents to treat TKI-refractory disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.